Overview

Proof-of-concept Trial of Apraglutide in GVHD

Status:
Recruiting
Trial end date:
2025-08-30
Target enrollment:
0
Participant gender:
All
Summary
The aim of this trial is to assess safety and efficacy of apraglutide in subjects with steroid refractory gastrointestinal acute graft versus host disease (aGVHD).
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
VectivBio AG
Criteria
Inclusion Criteria:

- Able to give informed consent and agree to follow the details of participation as
outlined in the protocol

- Male or female subjects aged 12 years or above at the time of consent and who weigh a
minimum of 40 kg

- Histologically confirmed lower GI-aGVHD at screening (MAGIC stage 1-4) with clinically
confirmed SR

- Have undergone alloSCT from any donor source

- Treated with SS plus RUX at recommended dose twice daily for 0-5 days prior to
enrolment/randomization)

- Clinically confirmed SR GI-aGVHD

- Women of childbearing potential (WOCBP): highly effective method of contraception
during the trial and for 4 weeks after the End of Trial (EOT) visit

- Male subjects with partner WOCBP: contraception and abstention from sperm donation
during the trial and for 2 weeks after the EOT visit

Exclusion Criteria:

- Treatment with any systemic GVHD therapy other than SS and RUX: methotrexate &
mycophenolate mofetil at the time of enrolment/randomization

- Concomitant treatment with Janus kinase inhibitor other than RUX

- Systemic corticosteroid therapy for indications other than aGVHD within 7 days prior
to screening

- Failed previous alloSCT

- Any use of enteral glutamine or GLP analogs Significant organ system failures
(respiratory renal hepatic and cardiac)

- Relapsed primary malignancy GI tumors or colonic polyps

- Active clinically uncontrolled infection

- Known chronic GVHD

- Known active GI inflammation not related to GI-aGVHD

- Major abdominal surgery in the last 6-months prior to screening and history of
clinically significant intestinal adhesions

- Abnormal liver function tests